Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

VASCUL-AID Developing Trustworthy Artificial Intelligence (ai)-driven Tools to Predict Vascular Disease Risk and Progression

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 May 2023 to 30 April 2029
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
21 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101080947

What the project is doing

In the project's own words, from its summary on CORDIS.

The aim of VASCUL-AID is to predict the risk of cardiovascular events and progression of the vascular diseases Abdominal Aortic Aneurysm (AAA) and Peripheral Arterial Disease (PAD) to influence the course of disease improving the patient’s quality of life and care and assisting clinicians to make better-informed decisions involving the patient. VASCUL-AID will allow us for the first time to identify patients who are at high risk for AAA growth or PAD progression and cardiovascular events.

To this end, we will deliver a clinically relevant and cost-effective trustworthy AI-driven platform (VASCUL-AID) that integrates multi-source parameters including imaging, proteomic and genomic data as well as life-style patient data from wearables to enable personalised vascular disease management. To maximise the personalised prevention strategies, VASCUL-AID leverages visualisation tools to improve clinician-patient communication and empower the patient.

The VASCUL-AID platform consists of AI risk-prediction tools, a patient communication app an a clinical dashboard to support clinical decision-making. A particular emphasis is placed on ethics, to ensure beneficial implementation of AI prediction tools. In this project, we aim to (1) build an EU-wide data infrastructure, (2) develop an AI-based progression prediction tools for AAA and PAD, (3) develop criteria according to the COMET initiative to assess the effectiveness of VASCUL-AID, and (4) clinically test and show proof-of-concept for the VASCUL-AID platform.

Once validated, this platform can be extended to other cardiovascular diseases (CVDs) as well. VASCUL-AID brings together 19 leading international organisations consisting of clinical academic centres, research institutes, universities and SMEs as well as large industry, patients organisations and policy makers that cover the full value chain to enable integration of the platform into clinical practice.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Brightfish BeTervurenBelgiumParticipant
Asklepios Kliniken Hamburg GmbHHamburgGermanyAssociatedpartner
Asklepios Kliniken Hamburg GmbHHamburgGermanyParticipant
Medizinische Hochschule Brandenburg Campus GmbHNeuruppinGermanyParticipant
Rwth Aachen Campus GmbHAachenGermanyAssociatedpartner
Hus-YhtymaHelsinkiFinlandParticipant
Centre Hospitalier Universitaire De NiceNiceFranceParticipant
Azienda Unita' Sanitaria Locale Toscana CentroFirenzeItalyAssociatedpartner
Stichting Allai NederlandAmsterdamNetherlandsParticipant
Universiteit TwenteEnschedeNetherlandsParticipant
Universitetet I BergenBergenNorwayParticipant
Unidade Local De Saude De Sao Joao, E.p.e.PortoPortugalThird party
Universidade De AveiroAveiroPortugalThird party
Universidade Do PortoPortoPortugalParticipant
Faculty of Medicine, University of BelgradeBelgradeSerbiaParticipant
Institut Za Nuklearne Nauke Vinca Institut Od Nacionalnog Znacaja Za Republiku Srbiju, Univerzitet U BegraduVinca BeogradSerbiaParticipant
Guys and St Thomas' Nhs FoundationtrustLondonUnited KingdomAssociatedpartner
King's College LondonLondonUnited KingdomAssociatedpartner
Oxford University Hospitals Nhs Foundation TrustHeadingtonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI